Chilly and flu drugs together with Nyquil sits on a retailer shelf on September 12, 2023 in Miami, Florida.
Joe Raedle | Getty Photos
The principle ingredient utilized in many standard over-the-counter chilly and allergy medicines does not really work to do away with nasal congestion, an advisory panel to the Meals and Drug Administration declared Tuesday.
In a unanimous vote, 16 advisors mentioned oral types of phenylephrine – a nasal decongestant present in variations of medicine like Nyquil, Benadryl, Sudafed and Mucinex – aren’t efficient at relieving a stuffy nostril.
The FDA usually follows the recommendation of its advisory committees however it isn’t required to take action. The company may probably transfer to start a course of that removes phenylephrine from the market, which might drive producers to tug broadly used cough and chilly medicines from retailer cabinets and reformulate these merchandise.
That would have an effect on Procter & Gamble, the producer of all variations of Nyquil, and the Johnson & Johnson spinoff Kenvue, which manufactures Tylenol and Benadryl merchandise.
The Shopper Healthcare Merchandise Affiliation, a commerce group representing producers and distributors of OTC medicine, mentioned Tuesday that it’s “disenchanted” by the advisory panel’s vote.
“We encourage FDA, earlier than making any regulatory willpower, to be conscious of the totality of the proof supporting this long-standing OTC ingredient, in addition to the considerably adverse unintended penalties related to any potential change” to phenylephrine’s regulatory standing, Scott Melville, the group’s CEO, mentioned in an announcement.
Pulling phenylephrine from the market may additionally have an effect on retail pharmacy chains, which rake in income from promoting over-the-counter chilly and allergy capsules.
Retail shops within the U.S. bought 242 million bottles of medicine containing phenylephrine final yr, up 30% from 2021, in keeping with information compiled by FDA workers. These generated $1.8 billion in gross sales final yr, the information mentioned.
With out oral phenylephrine, sufferers will doubtless be compelled to hunt out liquid and spray variations of the drug or solely new medicines, which weren’t included within the overview by the FDA advisors.
The 2-day advisory panel assembly was prompted by researchers on the College of Florida, who petitioned the FDA to take away phenylephrine merchandise primarily based on latest research exhibiting they didn’t outperform placebo capsules in sufferers with chilly and allergy congestion.
The identical researchers additionally challenged the drug’s effectiveness in 2007, however the FDA allowed the merchandise to stay available on the market pending extra analysis.
But FDA workers, in briefing paperwork posted forward of the assembly this week, concluded that oral formulations of phenylephrine do not work at normal and even increased doses. A really small quantity of the drug really reaches the nostril to alleviate congestion, the company’s workers mentioned.
